Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5619 in adults with inattentive-predominant ADHD
NCT01472991Phase 2Completed
- Sponsor
- Targacept
- Start
- Nov 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bradanicline in attention deficit hyperactivity disorder (ADHD), sponsored by Targacept. Started Nov 2011; status: completed.
02
Drugs
bradanicline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01472991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01472991.